Alligator Bioscience AB (publ) (0RK9.L)

1.1200 -0.1220 (-9.82%) At close: 09:35AM BST

Alligator Bioscience AB (publ)

Medicon Village
Scheelevägen 2
Lund 223 81
Sweden
46 4 65 40 82 00
https://www.alligatorbioscience.se

Sector(s): 
Industry: 
Full-time employees: 58

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Søren Bregenholt Ph.D.	Chief Executive Officer	5.2M	N/A	1971
Ms. Marie Svensson	Chief Financial Officer	N/A	N/A	1964
Ms. Laura von Schantz	Chief Technology Officer	N/A	N/A	1982
Dr. Peter Ellmark Ph.D.	Chief Scientific Officer	N/A	N/A	1973
Ms. Julie Silber	Director of Communications & Investor Relations	N/A	N/A	N/A
Dr. Sumeet Ambarkhane M.D.	Chief Medical Officer	N/A	N/A	1968

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company's product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, an immunostimulatory antibody, which is in phase 1 clinical trial for the treatment of metastatic cancer. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus Inc.; BioArctic AB; and Abclon Inc. The company was founded in 2000 and is headquartered in Lund, Sweden.

Corporate governance

Alligator Bioscience AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.